Lipella Pharmaceuticals (LIPO) Stock Overview
A clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LIPO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lipella Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$7.31 |
| 52 Week Low | US$0.17 |
| Beta | -0.013 |
| 1 Month Change | -44.66% |
| 3 Month Change | -73.31% |
| 1 Year Change | -94.61% |
| 3 Year Change | -99.31% |
| 5 Year Change | n/a |
| Change since IPO | -99.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIPO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.0% | -2.0% | -1.0% |
| 1Y | -94.6% | 23.0% | 14.9% |
Return vs Industry: LIPO underperformed the US Biotechs industry which returned 22.9% over the past year.
Return vs Market: LIPO underperformed the US Market which returned 14.7% over the past year.
Price Volatility
| LIPO volatility | |
|---|---|
| LIPO Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LIPO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LIPO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6 | Jon Kaufman | lipella.com |
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc. Fundamentals Summary
| LIPO fundamental statistics | |
|---|---|
| Market cap | US$790.16k |
| Earnings (TTM) | -US$5.33m |
| Revenue (TTM) | US$389.78k |
Is LIPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPO income statement (TTM) | |
|---|---|
| Revenue | US$389.78k |
| Cost of Revenue | US$3.57m |
| Gross Profit | -US$3.18m |
| Other Expenses | US$2.15m |
| Earnings | -US$5.33m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | -815.47% |
| Net Profit Margin | -1,367.37% |
| Debt/Equity Ratio | 0% |
How did LIPO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 20:16 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lipella Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |